Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer: ECOG 5597

Daniel D. Karp, Sandra J. Lee, Steven M. Keller, Gail Shaw Wright, Seena Aisner, Steven Alan Belinsky, David H. Johnson, Michael R. Johnston, Gary Goodman, Gerald Clamon, Gordon Okawara, Randolph Marks, Eric Frechette, Worta McCaskill-Stevens, Scott M. Lippman, John Ruckdeschel, Fadlo R. Khuri

Research output: Contribution to journalArticle

61 Scopus citations

Abstract

Purpose Selenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non-small-cell lung cancer (NSCLC) receiving selenium supplementation. Patients and Methods Patients with completely resected stage I NSCLC were randomly assigned to take selenized yeast 200 <g versus placebo daily for 48 months. Participation was 6 to 36 months postoperatively and required a negative mediastinal node biopsy, no excessive vitamin intake, normal liver function, negative chest x-ray, and no other evidence of recurrence. Results The first interim analysis in October 2009, with 46% of the projected end points accumulated, showed a trend in favor of the placebo group with a low likelihood that the trial would become positive; thus, the study was stopped. One thousand seven hundred seventy-two participants were enrolled, with 1,561 patients randomly assigned. Analysis was updated in June 2011 with the maturation of 54% of the planned end points. Two hundred fifty-two SPTs (from 224 patients) developed, of which 98 (from 97 patients) were lung cancer (38.9%). Lung and overall SPT incidence were 1.62 and 3.54 per 100 person-years, respectively, for selenium versus 1.30 and 3.39 per 100 person-years, respectively, for placebo (P = .294). Five-year disease-free survival was 74.4% for selenium recipients versus 79.6% for placebo recipients. Grade 1 to 2 toxicity occurred in 31% of selenium recipients and 26% of placebo recipients, and grade ≥ 3 toxicity occurred in less than 2% of selenium recipients versus 3% of placebo recipients. Compliance was excellent. No increase in diabetes mellitus or skin cancer was detected. Conclusion Selenium was safe but conferred no benefit over placebo in the prevention of SPT in patients with resected NSCLC.

Original languageEnglish (US)
Pages (from-to)4179-4187
Number of pages9
JournalJournal of Clinical Oncology
Volume31
Issue number33
DOIs
StatePublished - Nov 20 2013

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Karp, D. D., Lee, S. J., Keller, S. M., Wright, G. S., Aisner, S., Belinsky, S. A., Johnson, D. H., Johnston, M. R., Goodman, G., Clamon, G., Okawara, G., Marks, R., Frechette, E., McCaskill-Stevens, W., Lippman, S. M., Ruckdeschel, J., & Khuri, F. R. (2013). Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer: ECOG 5597. Journal of Clinical Oncology, 31(33), 4179-4187. https://doi.org/10.1200/JCO.2013.49.2173